Jazz Pharmaceuticals plc
JAZZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001232524
In the last 90 days, Jazz Pharmaceuticals plc insiders filed 0 open-market purchases and 10 sales; 652 institutions reported holding it in 13F filings for Q2 2026, worth $15.5B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 3, 2026, 1:11 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $356.1M (8.3% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| Research and development | $782.7M | $884.0M | $849.7M | $590.5M | $505.7M |
| Selling, general and administrative | $1.81B | $1.39B | $1.34B | $1.42B | $1.45B |
| Operating income | -$430.2M | $716.6M | $578.6M | -$65.5M | $170.3M |
| Interest expense | – | – | $32.8M | $32.8M | $89.9M |
| Income tax | -$272.4M | -$91.4M | -$119.9M | -$158.6M | $216.1M |
| Net income | -$356.1M | $560.1M | $414.8M | -$224.1M | -$329.7M |
| EPS, basic | $-5.84 | $9.06 | $6.55 | $-3.58 | $-5.52 |
| EPS, diluted | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 |
| Weighted shares, basic | 61.0M | 61.8M | 63.3M | 62.5M | 59.7M |
| Weighted shares, diluted | 61.0M | 66.0M | 72.1M | 62.5M | 59.7M |
| Margins and growth | |||||
| Operating margin | -10.1% | 17.6% | 15.1% | -1.8% | 5.5% |
| Net margin | -8.3% | 13.8% | 10.8% | -6.1% | -10.7% |
| Revenue growth, year over year | +4.9% | +6.1% | +4.8% | +18.3% | +30.9% |
| Net income growth, year over year | −163.6% | +35.0% | – | – | −238.2% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Cash and equivalents | $1.39B | $2.41B | $1.51B | $881.5M | $591.4M |
| Accounts receivable | $830.7M | $716.8M | $705.8M | $651.5M | $563.4M |
| Inventory | $417.0M | $480.4M | $597.0M | $714.1M | $1.07B |
| Total current assets | $4.17B | $4.63B | $3.44B | $2.61B | $2.61B |
| Goodwill | $1.83B | $1.72B | $1.75B | $1.69B | $1.83B |
| Intangible assets | $4.43B | $4.76B | $5.42B | $5.79B | $7.15B |
| Total assets | $11.7B | $12.0B | $11.4B | $10.8B | $12.3B |
| Accounts payable | $122.1M | $77.9M | $102.8M | $90.8M | $100.3M |
| Short-term debt | $1.03B | $31.0M | $605.0M | $31.0M | $31.0M |
| Total current liabilities | $2.24B | $1.04B | $1.54B | $933.2M | $809.3M |
| Long-term debt | $4.33B | $6.08B | $5.11B | $5.69B | $6.02B |
| Shareholders' equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Operating cash flow | $1.36B | $1.40B | $1.09B | $1.27B | $778.5M |
| Capital expenditures | $58.8M | $38.1M | $24.0M | $29.0M | $27.6M |
| Free cash flow | $1.30B | $1.36B | $1.07B | $1.24B | $750.9M |
| Depreciation and amortization | $41.6M | $32.8M | $30.4M | $30.3M | $26.7M |
| Stock-based compensation | $291.1M | $248.0M | $226.8M | $222.0M | $189.0M |
| Share buybacks | $125.0M | $311.4M | $269.8M | $54.0K | $0 |
| Investing cash flow | -$1.51B | -$508.2M | -$163.1M | -$446.2M | -$5.21B |
| Financing cash flow | -$873.4M | $20.5M | -$305.3M | -$529.5M | $3.97B |
| Net change in cash | -$1.02B | $906.6M | $624.8M | $290.0M | -$466.3M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 6.8% | 6.1% | 5.9% | 6.1% | 6.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 26, 2026 | 64.2M | +5.6% | SEC |
| Jul 27, 2026 | 64.9M | +7.0% | SEC |
| Apr 28, 2026 | 62.7M | +1.8% | SEC |
| Apr 15, 2026 | 62.7M | +1.8% | SEC |
| Feb 17, 2026 | 61.6M | +1.4% | SEC |
| Oct 29, 2025 | 60.8M | +0.5% | SEC |
| Jul 30, 2025 | 60.7M | −1.8% | SEC |
| Apr 30, 2025 | 61.6M | −2.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.